Nucleoporin 107 Antibody [HRP]
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-76926H
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Human, Mouse, Rat
Applications
ELISA, Immunocytochemistry/ Immunofluorescence, Western Blot
Label
HRP
Antibody Source
Polyclonal Rabbit IgG
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Antibody was raised against a 20 amino acid synthetic peptide from near the center of human NUP107. The immunogen is located within amino acids 370 - 420 of NUP107. Amino Acid Squence: HDPNVNGGTELEPVEGNPYR
Reactivity Notes
0
Clonality
Polyclonal
Host
Rabbit
Isotype
IgG
Applications for Nucleoporin 107 Antibody [HRP]
Application
Recommended Usage
ELISA
Optimal dilutions of this antibody should be experimentally determined.
Immunocytochemistry/ Immunofluorescence
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Peptide affinity purified
Formulation
PBS
Preservative
No Preservative
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Nucleoporin 107
Alternate Names
nuclear pore complex protein Nup107, nucleoporin 107kDa, NUP84Nucleoporin Nup107,107 kDa nucleoporin
Gene Symbol
NUP107
Additional Nucleoporin 107 Products
Product Documents for Nucleoporin 107 Antibody [HRP]
Product Specific Notices for Nucleoporin 107 Antibody [HRP]
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...